Accure Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.63M
- Investors
-
9
Accure Therapeutics General Information
Description
Developer of translational medicine engine developing disease-modifying drugs designed to treat diseases related to the Central Nervous System (CNS). The company's offerings include developing drugs for severe orphan and non-orphan CNS diseases by accelerating the transition to the disease-modifying treatment of disabling brain disorders, enabling doctors to tackle diseases related to the central nervous system.
Contact Information
Website
www.accure.healthCorporate Office
- Torres R+D+I
- Baldiri Reixac 4-8
- 08028 Barcelona
- Spain
Corporate Office
- Torres R+D+I
- Baldiri Reixac 4-8
- 08028 Barcelona
- Spain
Accure Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Grant | 07-Apr-2025 | $1.63M | Completed | Clinical Trials - Phase 2 | ||
| 1. Early Stage VC (Series A) | 26-May-2020 | Completed | Clinical Trials - Phase 2 |
Accure Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Accure Therapeutics Patents
Accure Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4714940-A1 | Gelatinase inhibitors and use thereof | Pending | 23-Sep-2024 | ||
| WO-2026062257-A1 | Gelatinase inhibitors and use thereof | Pending | 23-Sep-2024 | ||
| AU-2021303440-A1 | 1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile | Active | 07-Jul-2020 | ||
| AU-2021303440-B2 | 1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile | Active | 07-Jul-2020 | ||
| CA-3185064-A1 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | Pending | 07-Jul-2020 | C07D207/16 |
Accure Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Accure Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Luxembourg National Research Fund | Corporation | |||
| Michael J. Fox Foundation | Limited Partner | |||
| Alta Life Sciences | Venture Capital | Minority | ||
| Asabys Partners | Venture Capital | Minority | ||
| Centre for Technological and Industrial Development | Venture Capital | Minority |
Accure Therapeutics Acquisitions (2)
Accure Therapeutics’s most recent deal was a Merger/Acquisition with Iproteos. The deal was made on 28-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Iproteos | 28-May-2020 | Merger/Acquisition | Drug Discovery | ||
| Bionure Farma | 20-May-2020 | Merger/Acquisition | Drug Discovery |
Accure Therapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Accure Therapeutics (Worldwide Development and Commercial Rights to Privosegtor in Barcelona, Spain) | Barcelona, Spain |
Accure Therapeutics FAQs
-
When was Accure Therapeutics founded?
Accure Therapeutics was founded in 2020.
-
Where is Accure Therapeutics headquartered?
Accure Therapeutics is headquartered in Barcelona, Spain.
-
What is the size of Accure Therapeutics?
Accure Therapeutics has 12 total employees.
-
What industry is Accure Therapeutics in?
Accure Therapeutics’s primary industry is Drug Discovery.
-
Is Accure Therapeutics a private or public company?
Accure Therapeutics is a Private company.
-
What is Accure Therapeutics’s current revenue?
The current revenue for Accure Therapeutics is .
-
How much funding has Accure Therapeutics raised over time?
Accure Therapeutics has raised $8.28M.
-
Who are Accure Therapeutics’s investors?
Luxembourg National Research Fund, Michael J. Fox Foundation, Alta Life Sciences, Asabys Partners, and Centre for Technological and Industrial Development are 5 of 9 investors who have invested in Accure Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
